Association of early immune-related adverse events with treatment efficacy of neoadjuvant Toripalimab in resectable advanced non-small cell lung cancer

Overview of attention for article published in Frontiers in oncology, May 2023

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Good Attention Score compared to outputs of the same age and source (72nd percentile)

Mentioned by

twitter: 2 X users

Citations

dimensions_citation: 4 Dimensions

Readers on

mendeley: 3 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 2 X posts from 2 X users, with an upper bound of 6,660 followers.

Association of early immune-related adverse events with treatment efficacy of neoadjuvant Toripalimab in resectable advanced non-small cell lung cancer https://t.co/J3qDN0G2RL https://t.co/Ibt4LG3XgP

31 May 2023

Reply Repost Favourite

New research: Association of early immune-related adverse events with treatment efficacy of neoadjuvant Toripalimab in resectable advanced non-small cell lung cancer: Background Neoadjuvant immunotherapy with anti-PD-1 was proved promising in… #oncology h

25 May 2023

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.